Objective: Superficial tumors including Ta, Tis, and T1 make up 75% of urothelial carcinomas of the bladder. While the behavior of these superficial urothelial cancers is relatively benign, invasive tumors have a significant mortality rate. However, Ta and T1 tumors might display different biological behavior. There is therefore a great need for biomarkers that can accurately distinguish the behavior of urothelial carcinomas in addition to tumor grade and stage. our aim was to determine the immunohistochemical expression profile of insulin like growth factor ii mrna binding Protein 3 (iMP3) and its correlation with tumor stage and grade in benign urothelium and bladder urothelial carcinomas. Material and Method: The expression of iMP3 in 91 patients with benign urothelium (20 cases), low grade invasive (17 cases) / non-invasive (20 cases) urothelial carcinoma and high grade invasive (20 cases) / non-invasive (14 cases) urothelial carcinoma was evaluated by immunohistochemistry in this study. Results: iMP3 was not expressed in benign urothelium, low-grade non-invasive urothelial carcinoma and high grade non-invasive urothelial carcinoma. Expression of iMP3 was found in 11.76% of low-grade invasive urothelial carcinomas and 55% of high grade invasive urothelial carcinomas. Statistical analysis including χ2 tests showed that iMP3 expression of invasive urothelial carcinomas was statistically significant (p<0.000). Conclusion: The detection of iMP3 only in invasive carcinomas although some of them were low grade showed that the expression of iMP3 may be related to aggressive behavior of urothelial carcinomas. ÖZ Amaç: Ürotelyal karsinomların %75'i yüzeyel tümörler olarak Ta, Tis ve T1 şeklinde karşımıza çıkmaktadır. Yüzeyel tümörler benign davranış gösterirken, invaziv tümörlerde ise yüksek mortalite oranı bildirilmiştir. Bununla birlikte, Ta ve T1 tümörler, farklı biyolojik davranışlar sergileyebilmektedirler. Bu durum, ürotelyal karsinomların davranışının belirlenmesinde, histopatolojik evre ve dereceye ek olarak, bazı biyolojik belirteçlere ihtiyaç olduğunu göstermektedir. Bu çalışmada amacımız, benign ürotelyum ile mesanenin ürotelyal karsinomlarında insulin like growth factor ii mrna binding Protein 3 (iMP3) ekspresyon profilini belirleyerek, tümörün histopatolojik evresi ve derecesi ile ilişkisini saptamaktır. Gereç ve Yöntem: Bu çalışmada 91 hastaya ait benign ürotelyum (20 olgu), düşük dereceli invaziv (17 olgu) / non-invaziv (20 olgu) ürotelyal karsinom ve yüksek dereceli invaziv (20 olgu) / non-invaziv (14 olgu) ürotelyal karsinom tanısı almış olgular immünohistokimyasal olarak iMP3 ekspresyonu açısından değerlendirildi. Bulgular: Benign ürotelyum, düşük dereceli non-invaziv ürotelyal karsinom ve yüksek dereceli non-invaziv ürotelyal karsinom tanısı almış olgularda iMP3 ekspresyonu saptanmadı. Düşük dereceli invaziv ürotelyal karsinom olgularının %11,76'sında, yüksek dereceli invaziv ürotelyal karsinom olgularının %55'inde iMP3 ekspresyonu saptandı. χ2 testi ile yapılan istatistiksel analizde, invaziv tümö...
Activated B and T cells express COX-1 and COX-2 in paraffin-embedded tissue sections of chronic tonsillitis. Further studies need to be performed to elucidate expression of COX enzymes and their immunologic role in tonsil diseases. They will play an important role in the treatment of chronic tonsillitis. Additional studies are warranted to study the effects of NSAIDs and selective COX-2 inhibitors in chronic tonsillitis.
Objective: Superficial tumors including Ta, Tis, and T1 make up 75% of urothelial carcinomas of the bladder. While the behavior of these superficial urothelial cancers is relatively benign, invasive tumors have a significant mortality rate. However, Ta and T1 tumors might display different biological behavior. There is therefore a great need for biomarkers that can accurately distinguish the behavior of urothelial carcinomas in addition to tumor grade and stage. our aim was to determine the immunohistochemical expression profile of insulin like growth factor ii mrna binding Protein 3 (iMP3) and its correlation with tumor stage and grade in benign urothelium and bladder urothelial carcinomas. Material and Method: The expression of iMP3 in 91 patients with benign urothelium (20 cases), low grade invasive (17 cases) / noninvasive (20 cases) urothelial carcinoma and high grade invasive (20 cases) / non-invasive (14 cases) urothelial carcinoma was evaluated by immunohistochemistry in this study. Results: iMP3 was not expressed in benign urothelium, low-grade non-invasive urothelial carcinoma and high grade non-invasive urothelial carcinoma. Expression of iMP3 was found in 11.76% of low-grade invasive urothelial carcinomas and 55% of high grade invasive urothelial carcinomas. Statistical analysis including χ2 tests showed that iMP3 expression of invasive urothelial carcinomas was statistically significant (p<0.000). Conclusion: The detection of iMP3 only in invasive carcinomas although some of them were low grade showed that the expression of iMP3 may be related to aggressive behavior of urothelial carcinomas.
Objective: Superficial tumors including Ta, Tis, and T1 make up 75% of urothelial carcinomas of the bladder. While the behavior of these superficial urothelial cancers is relatively benign, invasive tumors have a significant mortality rate. However, Ta and T1 tumors might display different biological behavior. There is therefore a great need for biomarkers that can accurately distinguish the behavior of urothelial carcinomas in addition to tumor grade and stage. our aim was to determine the immunohistochemical expression profile of insulin like growth factor ii mrna binding Protein 3 (iMP3) and its correlation with tumor stage and grade in benign urothelium and bladder urothelial carcinomas. Material and Method:The expression of iMP3 in 91 patients with benign urothelium (20 cases), low grade invasive (17 cases) / noninvasive (20 cases) urothelial carcinoma and high grade invasive (20 cases) / non-invasive (14 cases) urothelial carcinoma was evaluated by immunohistochemistry in this study.Results: iMP3 was not expressed in benign urothelium, low-grade non-invasive urothelial carcinoma and high grade non-invasive urothelial carcinoma. Expression of iMP3 was found in 11.76% of low-grade invasive urothelial carcinomas and 55% of high grade invasive urothelial carcinomas. Statistical analysis including χ2 tests showed that iMP3 expression of invasive urothelial carcinomas was statistically significant (p<0.000). Conclusion:The detection of iMP3 only in invasive carcinomas although some of them were low grade showed that the expression of iMP3 may be related to aggressive behavior of urothelial carcinomas.Key Words: Urinary bladder, Urothelial carcinoma, iMP3, Transitional cell carcinoma ÖZ Amaç: Ürotelyal karsinomların %75'i yüzeyel tümörler olarak Ta, Tis ve T1 şeklinde karşımıza çıkmaktadır. Yüzeyel tümörler benign davranış gösterirken, invaziv tümörlerde ise yüksek mortalite oranı bildirilmiştir. Bununla birlikte, Ta ve T1 tümörler, farklı biyolojik davranışlar sergileyebilmektedirler. Bu durum, ürotelyal karsinomların davranışının belirlenmesinde, histopatolojik evre ve dereceye ek olarak, bazı biyolojik belirteçlere ihtiyaç olduğunu göstermektedir. Bu çalışmada amacımız, benign ürotelyum ile mesanenin ürotelyal karsinomlarında insulin like growth factor ii mrna binding Protein 3 (iMP3) ekspresyon profilini belirleyerek, tümörün histopatolojik evresi ve derecesi ile ilişkisini saptamaktır. Gereç ve Yöntem:Bu çalışmada 91 hastaya ait benign ürotelyum (20 olgu), düşük dereceli invaziv (17 olgu) / non-invaziv (20 olgu) ürotelyal karsinom ve yüksek dereceli invaziv (20 olgu) / non-invaziv (14 olgu) ürotelyal karsinom tanısı almış olgular immünohistokimyasal olarak iMP3 ekspresyonu açısından değerlendirildi. Bulgular:Benign ürotelyum, düşük dereceli non-invaziv ürotelyal karsinom ve yüksek dereceli non-invaziv ürotelyal karsinom tanısı almış olgularda iMP3 ekspresyonu saptanmadı. Düşük dereceli invaziv ürotelyal karsinom olgularının %11,76'sında, yüksek dereceli invaziv ürotelyal karsinom olgularının %55'inde...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.